Eligibility of patients with Staphylococcus aureus bacteraemia for early oral switch

Lancet Infect Dis. 2024 Apr;24(4):e209-e210. doi: 10.1016/S1473-3099(24)00065-3. Epub 2024 Jan 31.

Authors

George Cooper¹, Heather W Dolby¹, Karla Berry², Clark D Russell³

Affiliations

¹ Centre for Inflammation Research, Institute for Regeneration and Repair, The University of Edinburgh, Edinburgh EH16 4UU, UK.
² Clinical Infection Research Group, Western General Hospital, Edinburgh, UK.
³ Centre for Inflammation Research, Institute for Regeneration and Repair, The University of Edinburgh, Edinburgh EH16 4UU, UK. Electronic address: clark.russell@ed.ac.uk.

PMID: 38309279
DOI: 10.1016/S1473-3099(24)00065-3

No abstract available

Publication types

Letter

MeSH terms

Anti-Bacterial Agents / therapeutic use
Bacteremia* / drug therapy
Humans
Methicillin-Resistant Staphylococcus aureus*
Staphylococcal Infections* / drug therapy
Staphylococcus aureus

Substances

Anti-Bacterial Agents